Elizabeth Fetherston, S. Tee, `Meilan Kwok, Satish Artham, P. Carey, R. Nayar, D. Bishop, A. Joshi
{"title":"使用简化的局部指南可改善COVID-19住院患者糖尿病和高血糖的“前门”管理","authors":"Elizabeth Fetherston, S. Tee, `Meilan Kwok, Satish Artham, P. Carey, R. Nayar, D. Bishop, A. Joshi","doi":"10.15277/bjd.2022.397","DOIUrl":null,"url":null,"abstract":"Background COVID-19, caused by the severe acute respiratory syndromecoronavirus-2 (SARS-CoV-2), was declared a pandemic on 11th March 2020. COVID-19 increases risk of hyperglycaemia regardless of prior diabetes diagnosis. Following results of the RECOVERY trial showing survival benefit in people with COVID-19 who required oxygen, dexamethasone has been used to improve outcomes.1 Dexamethasone (a glucocorticoid) may exacerbate hyperglycaemia in people with diabetes and can precipitate glucocorticoid-induced diabetes in others. In the context of COVID-19 infection, stress-related hyperglycaemia increases risk of mortality during hospitalization.2 In order to improve recognition and management of COVID-19-related hyperglycaemia, the National Diabetes Inpatient COVID response team published relevant guidance.3","PeriodicalId":42951,"journal":{"name":"British Journal of Diabetes","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Use of a simplified local guideline improves “front door” management of diabetes and hyperglycaemia in people admitted to hospital with COVID-19\",\"authors\":\"Elizabeth Fetherston, S. Tee, `Meilan Kwok, Satish Artham, P. Carey, R. Nayar, D. Bishop, A. Joshi\",\"doi\":\"10.15277/bjd.2022.397\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background COVID-19, caused by the severe acute respiratory syndromecoronavirus-2 (SARS-CoV-2), was declared a pandemic on 11th March 2020. COVID-19 increases risk of hyperglycaemia regardless of prior diabetes diagnosis. Following results of the RECOVERY trial showing survival benefit in people with COVID-19 who required oxygen, dexamethasone has been used to improve outcomes.1 Dexamethasone (a glucocorticoid) may exacerbate hyperglycaemia in people with diabetes and can precipitate glucocorticoid-induced diabetes in others. In the context of COVID-19 infection, stress-related hyperglycaemia increases risk of mortality during hospitalization.2 In order to improve recognition and management of COVID-19-related hyperglycaemia, the National Diabetes Inpatient COVID response team published relevant guidance.3\",\"PeriodicalId\":42951,\"journal\":{\"name\":\"British Journal of Diabetes\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2022-12-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Diabetes\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15277/bjd.2022.397\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15277/bjd.2022.397","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Use of a simplified local guideline improves “front door” management of diabetes and hyperglycaemia in people admitted to hospital with COVID-19
Background COVID-19, caused by the severe acute respiratory syndromecoronavirus-2 (SARS-CoV-2), was declared a pandemic on 11th March 2020. COVID-19 increases risk of hyperglycaemia regardless of prior diabetes diagnosis. Following results of the RECOVERY trial showing survival benefit in people with COVID-19 who required oxygen, dexamethasone has been used to improve outcomes.1 Dexamethasone (a glucocorticoid) may exacerbate hyperglycaemia in people with diabetes and can precipitate glucocorticoid-induced diabetes in others. In the context of COVID-19 infection, stress-related hyperglycaemia increases risk of mortality during hospitalization.2 In order to improve recognition and management of COVID-19-related hyperglycaemia, the National Diabetes Inpatient COVID response team published relevant guidance.3
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
